Analyst Ratings February 13, 2026

Morgan Stanley Raises Allegro MicroSystems to Overweight, Sees 21.9% Upside

Bank cites recovery in volumes, durable automotive demand and growing industrial/data-center exposure as drivers for margin expansion

By Avery Klein ALGM
Morgan Stanley Raises Allegro MicroSystems to Overweight, Sees 21.9% Upside
ALGM

Morgan Stanley upgraded Allegro MicroSystems from Equalweight to Overweight and assigned a $51.00 price target, implying roughly a 21.9% upside from the current $41.83 share price. The firm points to the company’s positioning at the intersection of a cyclical recovery and secular tailwinds in automotive electronics, alongside industrial and emerging data-center applications, as the rationale for the upgrade. Recent quarterly results beat expectations, the company launched a precision Hall-effect current sensor, and internal leadership shifts aim to strengthen operations and technology execution.

Key Points

  • Morgan Stanley upgraded Allegro MicroSystems to Overweight with a $51.00 price target, implying roughly 21.9% upside from $41.83.
  • The firm cites a blend of cyclical recovery and durable secular demand in automotive electronics, plus industrial and data-center opportunities, as the rationale for the upgrade.
  • Recent results beat expectations (Q3 2026 EPS $0.15 vs $0.14 forecast; revenue $229.2M vs $220.79M) and the company introduced the ACS37017 Hall-effect current sensor; leadership promotions aim to strengthen operations and technology execution.

Morgan Stanley upgraded Allegro MicroSystems (ALGM) from Equalweight to Overweight and set a $51.00 price target, signaling an implied upside of approximately 21.9% from a prevailing share price of $41.83.

The research note frames Allegro as positioned where a cyclical recovery intersects with ongoing secular growth trends, particularly in automotive end markets. Morgan Stanley emphasized the company's powertrain-agnostic portfolio as a structural advantage that could support sustained revenue growth relative to both global light vehicle production and automotive semiconductor peers in 2026 and 2027.

Performance data cited alongside the upgrade show strong recent price appreciation for the stock - a roughly 70.25% gain over the past year and a 58.57% increase year-to-date - underscoring investor interest as the company navigates the recovery.

Beyond automotive, Morgan Stanley highlighted the industrial segment as a meaningful driver of future expansion. Within that segment, the firm pointed to nascent opportunities in data center applications tied to thermal management and power. Those data-center related sales represented about 10% of revenue in the December quarter and are estimated to account for about 8% of calendar year 2025 revenue.

Analyst estimates incorporated in the outlook show an expectation for revenue growth of 22% in fiscal 2026, and the note referenced five analyst upward revisions to upcoming earnings estimates. Morgan Stanley sees room for gross margin and operating margin expansion as volumes recover and the company’s product mix shifts toward higher-value technologies such as tunnel magnetoresistance (TMR) sensors and gate drivers.

Margin support is also expected to come from supply-chain diversification and disciplined control of operating expenses. The company’s liquidity position was highlighted as strong, with a current ratio of 3.65 indicating that liquid assets comfortably exceed short-term liabilities.

The firm acknowledged that Allegro had set a prior long-term model just before a 2023 peak and the subsequent inventory-driven downturn in 2024, but noted execution has remained steady through that cycle. Morgan Stanley suggested refreshed targets are likely to reflect a more stable economic backdrop.

Although Allegro has not been profitable over the last twelve months, consensus forecasts point to a return to profitability this year, with an expected EPS of $0.53.


Recent company announcements and results provide additional context to the upgrade. In Q3 2026 Allegro reported adjusted earnings per share of $0.15, versus a consensus expectation of $0.14, and generated $229.2 million in revenue compared with an anticipated $220.79 million. These results demonstrate a modest beat on both the top and bottom lines for the quarter.

On the product front, Allegro introduced the ACS37017 Hall-effect current sensor. The device is factory-calibrated and is specified to deliver a typical sensitivity error of 0.55% over its lifetime, targeting high-voltage power conversion system applications.

Leadership moves announced by the company include the promotion of Ian Kent to Senior Vice President, Operations and Jamie Haas to Vice President, Chief Technology Officer. Kent, who joined Allegro in 2023, has been tasked with overseeing worldwide manufacturing and supply chain operations.

Taken together, the upgrade, recent financial beats, new product introductions and leadership changes form the basis of Morgan Stanley’s more bullish stance, as the firm anticipates revenue recovery, improving margins and continued secular support from automotive and industrial end markets.

Risks

  • Allegro was not profitable over the last twelve months - return to sustained profitability is forecast but not yet realized, posing an earnings risk to investors.
  • Prior long-term targets were set before a 2023 peak and a 2024 inventory-driven downturn; future performance could be sensitive to inventory cycles and end-market demand.
  • Margin expansion projections rely on volume recovery and a favorable shift in product mix toward higher-value technologies; slower volume recovery or an adverse mix could limit margin improvement.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026